microdosing tirzepatide for autoimmune GLP-1 Agonists: A New Frontier in Metabolic and Immune Health Microdosing GLP-1s: Does It Work?

Most patients see noticeable appetite reduction within the first week and measurable weight loss by week three to four

Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies

Patients were initiated at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to dose levels of 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg per week), aiming at reaching the maintenance dose of 2.4 mg (or the corresponding volume of placebo) after 16 weeks

Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of tuberous sclerosis complex